Bordetella pertussis is the noninvasive respiratory tract pathogen which causes whooping cough. With decreasing incidence of this disease, there is increasing concern regarding the reactivity of the current vaccine (15, 22) . Research on an improved vaccine has been hampered by both the fastidious growth characteristics of this organism and by its proclivity for rapid genetic and phenotypic variation. Most solid and liquid media inhibit the growth of B. pertussis, and it elaborates products that are toxic to itself (22, 26, 27) . In addition, the organism undergoes two different types of phenotypic changes which result in the loss of virulence-associated factors. The first, modulation, manifests itself as a reversible, environmentally regulated loss and reacquisition of virulence-associated factors (18). The second type, degradation, appears to be caused by mutation in the vir gene which results in the coordinate loss of virulence-associated factors (45). Vaccines produced from organisms which lack virulence-associated factors do not provide immunity to virulent organisms (22, 25) .
Bordetella pertussis is the noninvasive respiratory tract pathogen which causes whooping cough. With decreasing incidence of this disease, there is increasing concern regarding the reactivity of the current vaccine (15, 22) . Research on an improved vaccine has been hampered by both the fastidious growth characteristics of this organism and by its proclivity for rapid genetic and phenotypic variation. Most solid and liquid media inhibit the growth of B. pertussis, and it elaborates products that are toxic to itself (22, 26, 27) . In addition, the organism undergoes two different types of phenotypic changes which result in the loss of virulence-associated factors. The first, modulation, manifests itself as a reversible, environmentally regulated loss and reacquisition of virulence-associated factors (18) . The second type, degradation, appears to be caused by mutation in the vir gene which results in the coordinate loss of virulence-associated factors (45) . Vaccines produced from organisms which lack virulence-associated factors do not provide immunity to virulent organisms (22, 25) .
B. pertussis expresses several virulence-associated factors, the best studied of which are pertussis toxin (PT), filamentous hemagglutinin (FHA), agglutinogens, demonecrotic toxin, and adenylate cyclase (13, 22, 26, 47) . Research on an acellular component vaccine has been directed toward the use of PT and FHA (33) . Active or passive immunization against PT gives protection against aerosol challenge from the organism, whereas active, but not passive, immunization against FHA protects against aerosol challenge (23, 31) .
More importantly, simultaneous active or passive immunization against both proteins has a synergistic effect. Both PT and FHA are hemagglutinins and have been reported to act in concert as adhesins to human ciliated epithelial cells. Interest has been shown in the possibility of a vaccine which blocks adherence of B. pertussis (42, 43) . The agglutinogens, as well as PT and FHA, are implicated as mediators of attachment in assays with tissue culture cells (13, 29) .
The FHA is a candidate for inclusion in an improved vaccine. Several laboratories report that purified FHA consists of a heterogeneous population of polypeptides, as * Corresponding author.
revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (2, 5, 16) . Arai and Sato suggested that FHA fragmentation might be due to proteolytic cleavage (2) . Evidence to support this suggestion was presented by Irons et al. (16) . The FHA from B. pertussis Tohama 1 showed multiple bands with molecular masses ranging from 160 to 52 kilodaltons (kDa). For strain Wellcome 28, the molecular sizes of FHA bands ranged between 220 and 89 kDa. Preparations of FHA which lacked the 220-and 210-kDa components showed reduced specific hemagglutinating activity (16) .
We undertook the cloning of B. pertussis DNA because of the interest in developing an acellular vaccine. We report here the cloning and expression of the structural gene for FHA and provide evidence that we have also cloned a gene controlling the expression of FHA in B. pertussis.
MATERIALS AND METHODS
Bacterial strains and plasmids. B. pertussis UT25 was isolated from a pertussis outbreak in Texas (9) . B. pertussis BP353, a Tn5-induced FHA mutant and its parent, BP338, a nalidixic acid (50 ,ug/ml)-resistant derivative of strain Tohama 1, the Japanese vaccine strain, were kindly provided by A. Weiss (33, 46) . A spontaneous streptomycinresistant (Smr) variant of strain BP353 was isolated in this laboratory on media containing 100 ,Lg of streptomycin per ml. Escherichia coli LE392 (40) was used as the cloning recipient. Cosmid pCP13 (7) and plasmids pBR322, pBR328 (37), pMK16 (17) , and pRK2013 (10) were used in this study. The B. pertussis strains were stored in defibrinated sheep blood (Hazelton Research Products, Inc., Denver, Pa.) at -70°C. E. coli LE392 was stored in 15% glycerol in brain heart infusion medium (Difco Laboratories, Detroit, Mich.) at -70°C. All strains were lyophilized in 10% skim milk medium (Difco) for long-term storage.
Media and cultural conditions. B. pertussis strains were grown on homemade Bordet-Gengou agar with 20% defibrinated sheep blood (4 (20) . FHA from B. pertussis 18334 was purified at the Michigan Department of Health by the procedure of Sato et al. (32) , and was a gift of L. Winberry. The purified FHA was used as a positive control at 0.005 mg of protein per ml. A SO-,ul volume of each sample was added to the first well of a microtiter plate and twofold serially diluted 11 times. Then, 50 ,lI of 0.05% sheep erythrocytes in phosphate-buffered saline was added to each well, and the plates were held at room temperature for 3 h for HA to occur. The data were expressed as specific activity, calculated as the inverse of the amount of protein (milligrams) in the well with the highest dilution that gave complete HA.
Antisera. Rabbit anti-B. pertussis antiserum was obtained from a female New Zealand White rabbit (Wallenburn Rabbitry, Otterville, Mo.) immunized twice weekly for 4 weeks with 0.5 ml of a B. pertussis UT25 vaccine prepared from cells grown in SS broth (11) . The antiserum was absorbed twice with E. coli LE392(pCP13) cells. Rabbit anti-FHA was made at the Michigan Department of Health and was a gift of L. Winberry. Monoclonal antibody (MAb) 12H3 was produced in this laboratory (11) Rl of rabbit anti-B. pertussis antiserum. The filters were kept at 4°C overnight with rocking. The filters were rinsed 10 times with TS and placed in 200 ml of fresh blocking solution with 100pul of goat anti-rabbit IgG-peroxidase for 4 h at room temperature with rocking. The filters were then rinsed 10 times with TS, and then peroxidase was detected with the 4-chloronapthol reagent (14) . Protein immunoblots (Western blots). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was conducted with a 7.5% separating gel in the presence of 0.5 M urea as described elsewhere (8, 35) . Protein immunoblotting was performed as previously described (12, 41 (Fig. 1) , and for simplicity, the polypeptides produced by E. coli containing pDB441 were referred to as immunoreactive FHA (iFHA). The protein immunoblot was repeated on this clone with MAb 12H3, and high-molecular-mass bands at about 230, 215, 175, and 160 kDa were detected (Fig. 2, pDB441 ). The apparent molecular masses of these polypeptides were not identical to those of the FHA bands seen with B. pertussis UT25, which had molecular masses of about 215 (arrowhead), 210, 208, and 205 kDa (Fig. 2, UT25 ). Bands were also seen at about 150 and 140 kDa (Fig. 3, UT25 (Fig. 3, lanes BP353; see asterisk) . The Smr variant of strain BP353 produced the same protein immunoblot pattern with MAb 12H3 as was seen with original strain BP353 (data not shown). Weiss et al. (46) suggested that strain BP353 was defective in either the structural gene for FHA or a gene necessary for expression of the FHA. Our findings of reduced amounts of FHA polypeptides of apparently normal size from strain BP353 suggest that TnS exerted a polar effect or that it was inserted into a control gene rather than into the structural gene for FHA.
Attempts to transform pDB441 to B. pertussis BP353, the FHA mutant, were unsuccessful, presumably because of the large size of the plasmid and the inefficiency of transformation for B. pertussis relative to that for E. coli (42) . Furthermore, B. pertussis could not be isolated from the plate mating procedure when the original strain BP353 was used, because significant numbers of E. coli LE392 were able to grow in the presence of nalidixic acid. Conjugal transfer of pDB441 and pCP13 from E. coli to B. pertussis was successful when a Smr variant of BP353 was used as the recipient.
The protein immunoblots performed on transconjugants and control strains showed that B. pertussis strains UT25, BP338, and BP353(pDB441) had essentially the same pattern of FHA polypeptides (Fig. 3) . Strain UT25 was the DNA donor for the genomic library, and its FHA had polypeptides at 215, 210, 150, and 140 kDa. The data for strain BP338 were in agreement with that reported by Weiss et al. (46) . Strain BP338 is isogenic with strain BP353, and conjugal transfer of pDB441 to strain BP353 restored the parental level of expression of FHA. These two strains had the same FHA polypeptides as strain UT25 and a detectable fragment at 160 kDa (Fig. 3) . The faint bands at 220 kDa (no arrow-heads) in strains BP338 and BP353(pDB441) may be artifacts, because they were not consistently detected, but they did not affect the interpretation of the results. Since strain BP353 made detectable FHA, the restoration of FHA production by pDB441 was probably due to provision of a trans-acting factor necessary for the expression of FHA. The purified FHA from strain 18334 also showed the high-molecular-mass bands of 215 and 210 kDa. Molecular masses for all of the above FHA preparations were in agreement with those reported by Irons et al. (16) for the FHA strain Wellcome 28. These authors reported fragments of 220, 210, 142, 135, and 89 kDa. The molecular masses of the fragments from strain BP338, a Tohama 1 derivative, were much higher than those reported for strain Tohama 1 (2, 16), except for a 160-kDa band reported for Tohama 1 (5) . Our data suggested that fragmentation of FHA in our strains occurred by a similar, if not identical, mechanism, since we detected only minor strain differences. Perhaps the differences reported by other workers reflect various cultural conditions or purification protocols used.
HA assays were conducted on the B. pertussis strains to determine whether a functional FHA was restored by pDB441 (Table 1) . Strains UT25 and 13P338 had identical titers, and their specific activities for HA were essentially the same. The data showed that strain BP353 had no detectable ability to hemagglutinate sheep erythrocytes, confirming the earlier report (46) . Strain BP353, carrying the cloning vector pCP13, was also unable to hemagglutinate sheep erythrocytes. There was an eightfold increase in the HA titer and a 10-fold increase in the specific activity of HA for strain BP353(pDB441) over that seen with strain BP338. Transcription from multiple copies of the fha gene might explain the apparently elevated levels of FHA activity, but this did not explain why we did not see an apparent increase in the FHA antigen in the protein immunoblots (Fig. 3) . However, the HA assay measured activity, whereas immunoblots provided estimates of antigen levels, and the two procedures are not necessarily equivalent. Purified FHA was used as a positive control for HA, and the specific activity was essentially the same as that reported elsewhere (5, 32 ments into various plasmids: pDB2200 consisted of the 7-kbp EcoRI fragment cloned into the EcoRI site of pBR328; pDB2310 consisted of the 14-kbp XhoI fragment cloned into the XhoI site of pMK16; and pDB2150 consisted of the 15-kbp ClaI fragment cloned into the ClaI site of pBR322 (Fig. 1) . These plasmids were transformed into E. coli LE392, and the cells were analyzed for production of iFHA by protein immunoblots with MAb 12H3. None of them appeared to produce iFHA ( Fig. 2 ; data shown only for pDB2200, lane a). The protein immunoblot was repeated with rabbit anti-FHA, and pDB2200 was found to code for polypeptides which had molecular sizes of 210, 190, 175, and 160 kDa (Fig. 2, pDB2200, lane b) . Therefore, the fha gene was located at the left end of the 26.5-kbp insert of B. pertussis DNA in pDB441. The iFHA from pDB2200 lacked the MAb-binding site. This could be interpreted in several ways: the epitope was not coded on the EcoRI fragment, E. coli was not capable of expressing the polypeptide with a proper conformation, or subcloning into the EcoRI site of the Cmr gene had led to a fusion polypeptide which had an altered conformation such that only polyclonal rabbit anti-FHA could bind to it. TheJha gene must have extended beyond the 7-kbp EcoRI DNA fragment cloned to produce pDB2200, because the encoded iFHA were smaller than that from pDB441. A DNA fragment that was 1.6 kbp larger than this 7-kbp EcoRI fragment was constructed by digestion of pDB441 with ClaI, followed by religation. This plasmid, pDB2000, lacked the 15-, 4-, and 1-kbp ClaI fragments of pDB441 (Fig. 1) . The DNA of interest began at the left-hand EcoRI site of the polylinker of pDB441, extended through the first 31 bases of the Kmr gene and 8.3 kbp of B. pertussis DNA, and ended at the left-hand ClaI site (Fig. 1) . The BglII and PstI sites were mapped for this fragment (Fig. 4) . E. coli LE392(pDB2000) produced high amounts of iFHA relative to that produced by E. coli LE392(pDB441), as determined by the greater staining intensity with MAb 12H3 and an increase in the number of detectable bands. Production was maximal after 16 h of growth. Polypeptides were detected at 230, 225, 215, 205, 195, 185, 175, 160, and 117 kDa (Fig. 2, pDB2000 ). All the polypeptides seen with pDB441 were present in cells with pDB2000, including the polypeptides which were larger than FHA from B. pertussis (Fig. 2, UT25 ). Plasmid pDB2000 contained 1.6 kbp more B. pertussis DNA than did pDB2200, and the iFHA contained the MAb-binding site, but this finding was not sufficient to prove that the MAb-binding site was coded on this additional DNA fragment. To ensure that the entire iFHA was coded by pDB2000, the 4-kbp ClaI fragment of pDB441 (Fig. 1) was cloned into the ClaI site of pDB2000. There was no detectable difference in the pattern (Fig. 4) . The 5-kbp BamHI fragment, from 1.7 to 6.7 kbp on the map, was cloned into the BamHI site of pBR322 to construct pDB2130, which aided in mapping the other end of the fha gene. A polypeptide coded by this DNA fragment should have been detectable with rabbit anti-FHA only if this fragment contained the promoter for the fha gene or if a promoter was supplied by the Tcr gene into which it was cloned, since one end of the B. pertussis DNA would essentially be the same for the cloned fragments in pDB2130 and pDB2200 (Fig. 4) . No fragments of iFHA were detected from cells containing pDB2130, which seemed to rule out the possibility that this BamHI fragment contained the promoter for the Jha gene (Fig. 2, pDB2130, lane b) .
Regions to the left and right of the 5-kbp BamHI fragment appeared essential to iFHA expression in E. coli. We were able to show that the Kmr gene provided the promoter function for the transcription of the fha gene. Plasmids pDB2110 and pDB2120 were constructed by cloning (into ClaI-and Sall-digested pBR322) the 8.3-kbp fragment from the ClaI to XhoI (at 0 kbp) sites or the 7.9-kbp fragment from the ClaI to XhoI (at 0.4 kbp) sites of pDB2000, respectively (Fig. 4) . Neither plasmid expressed iFHA (Fig. 2, pDB2110 and pDB2120). Because all the insert DNA of pDB2000 was present in pDB2110, fha was evidently transcribed from left to right and was under the control of the Kmr gene promoter. Further evidence that the Kmr gene promoter was responsible for the synthesis of iFHA was obtained. The 3-kbp XhoI fragment, from 0.4 to 3.4 kbp on the map, was cloned in opposite orientations into the XhoI site of pMK16 to give pDB2300 and pDB2301 (Fig. 4) . Only cells with pDB2300 expressed a peptide of 127 kDa, which was detected by MAb 12H3 as well as by rabbit anti-FHA, which also detected a peptide of 97 kDa (Fig. 2, pDB2300 and pDB2301) . ' (Fig. 4) . The sequence of the Cmr gene indicates that there are four stop codons within 84 bases of the EcoRI site on the negative strand of pBR328, with at least one in each possible reading frame (1, 37) . Therefore, the maximum-size polypeptide that could be added to the iFHA polypeptide was 3.1 kDa, sincesite, or at map distance 1.0 kbp (Fig. 4) . Further evidence supporting this location for the site of the translation start signal came from a similar analysis of pDB2300 (24) . The translation start signal for iFHA was thus calculated to be at 0.7 kbp, which agreed well with results calculated for pDB2200 (Fig. 4) . There is a precedent for a Kmr promoter controlling distal gene expression. Berg et al. (3) have shown the Kmr promoter of Tn5-112, when inserted in the proper orientation, can stimulate basal level expression of lacZ. We suggest that a similar mechanism functions here.
The sequences that coded for the carboxyl terminal of the iFHA were determined from the polypeptides produced from pDB2000 and pDB2100. These plasmids contained additional DNA at the 3' end of the fha gene and coded for a polypeptide 17 kDa larger than the Jha gene-derived portion of the iFHA, as seen with pDB2200. The stop codon forJha was apparently located no more than 0.5 kbp to the right of the right-hand EcoRl site, or about map distance 7.2 kbp (Fig. 4) .
As evaluated by immunoblots, B. pertussis produced more FHA on a protein basis than E. coli produced iFHA. Efficient production of iFHA in E. coli might allow purification of an antigen useful for a pertussis vaccine and thereby might avoid problems with potentially toxic B. pertussis products. In an effort to increase iFHA production in E. coli, the fha gene was moved into ClaI-and EcoRI-digested pBR322, a multicopy plasmid, as a CiaI-partial EcoRI digestion fragment of pDB2000 to give pDB2100 (Fig. 4) . This fragment maintained the Kmr gene promoter, but expression of iFHA was poor, since only iFHA polypeptides of 230 and 175 kDa were detected with MAb 12H3 (Fig. 2, pDB2100 ). Maximal expression of iFHA occurred at 8 h of growth, with no iFHA detected at 16 h.
The FHA, PT, and the agglutinogens have been reported to be responsible for adherence of B. pertussis to cell surfaces (13, 42) . Prevention of adherence (and therefore initiation of infection) is a major goal in the development of an acellular vaccine (42) . Active or passive immunization of mice against PT toxoid protects them from aerosol challenge with B. pertussis. However, PT has been shown to be required for the occurrence of vaccine-associated encephalopathy in mice (39) . It has been suggested that PT may cause this same syndrome in certain susceptible individuals. Although immunization with FHA or administration of antisera to FHA may not protect mice against aerosol challenge with B. pertussis, simultaneous administration with PT or antisera to PT, respectively, greatly decreased the dose for PT or anti-PT needed to protect 50% of the mice. The synergistic immune response, when both PT and FHA were given, made FHA a prime candidate for inclusion in an acellular vaccine.
We have shown the Iha gene was 6.2 to 6.5 kbp long and extended from about 0.7 or 1.0 to 7.2 kbp on our map (Fig.  4) . We have evidence that the Kmr gene provided the promoter function for iFHA but that the translation start signal may have been as much as 1.0 kbp from this promoter. This evidence, taken with the elevated expression level of FHA in B. pertussis BP353(pDB441), suggested that pDB2000 probably contained the promoter for the jha gene, which did not function in E. coli in the absence of the vir gene (S. Stibitz and S. Falkow, Abstr. Annu. Meet. Am. Soc. Microbiol. 1986, D-80, p. 79). We suggest that pDB441 might code for a trans-acting factor which is required for proper expression of FHA in B. pertussis but is not required for expression of iFHA in E. coli. The intracellular location of iFHA and the inability of a multicopy plasmid to increase production of iFHA in E. coli may complicate purification of this protein from E. coli. However, this report on cloning and expression of FHA in both B. pertiussis and E. coli should provide useful recombinant techniques for the study of B. pertussis antigens in E. coli.
